Calliditas Therapeutics AB
(NASDAQ : CALT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.23%177.110.7%$1337.30m
MRKMerck & Co., Inc. -0.31%90.890.7%$1164.24m
PFEPfizer Inc. -1.30%51.750.9%$1099.24m
LLYEli Lilly & Co. -1.26%320.151.1%$1032.51m
BMYBristol-Myers Squibb Co. -1.08%76.171.0%$997.00m
ABBVAbbVie, Inc. -0.58%152.271.9%$953.16m
AZNAstraZeneca Plc -1.26%65.241.0%$435.93m
SGENSeagen Inc. 1.22%179.095.7%$319.73m
TPTXTurning Point Therapeutics, Inc. -0.09%75.190.0%$287.85m
GSKGSK Plc -0.35%43.380.2%$275.50m
NVSNovartis AG -1.04%83.650.2%$162.86m
HZNPHorizon Therapeutics Plc 0.44%80.115.4%$162.52m
MRTXMirati Therapeutics, Inc. 5.38%70.741.6%$154.60m
ALNYAlnylam Pharmaceuticals, Inc. 1.68%148.308.1%$142.88m
NVONovo Nordisk A/S -0.77%110.570.1%$142.12m

Company Profile

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Ã…ke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.